Glofitamab Plus Chemo Improves Survival vs Rituximab in R/R DLBCL
The phase 3 STARGLO trial met its primary end point, improving overall survival in patients with relapsed/refractory diffuse large B-cell lymphoma with glofitamab and chemotherapy vs rituximab and chemotherapy.